Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | MC5R | P33032 | 1/20 | 0.40 |
| ▸ | MC3R | P41968 | 1/20 | 0.40 |
| ▸ | MC1R | Q01726 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 9/20 | 0.38 |
| ▸ | CBLB | Q13191 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1645191 | 0.85 | GRN (0.44) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1285408 | 0.75 | PDE2A (0.49) | PDE2A | |
| SCHEMBL1285409 | 0.75 | PDE2A (0.49) | PDE2A | |
| SCHEMBL1285190 | 0.75 | PDE2A (0.41) | PDE2A | |
| SCHEMBL1285582 | 0.74 | PDE2A (0.46) | PDE2A | |
| SCHEMBL1285299 | 0.74 | PDE2A (0.46) | PDE2A | |
| SCHEMBL1644450 | 0.74 | S1PR3 (0.32) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1285137 | 0.74 | EPHX2 (0.41) | ALDH1A1 | |
| SCHEMBL1284842 | 0.73 | PDE2A (0.44) | PDE2A | |
| SCHEMBL1284794 | 0.72 | NPC1 (0.34) | KDM4EALDH1A1HPGDHSD17B10PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | MC4R 3006/4885MC5R 2397/4885MC3R 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.